Articles for Specialty Pharmaceuticals
August 12, 2014 |
Specialty drugs expected to account for 40% of total prescription spending by 2016, according to Catamaran Corporation.
June 30, 2014 |
Specialty pharmaceuticals are changing the lives of patients with cancer and chronic conditions, but their high cost and increased used has drawn the scrutiny of payers. A review in this month's issue of The American Journal of Managed Care, which examined studies involving therapies for rheumatoid arthritis, multiple sclerosis, and breast cancer, found that when these drugs are used with the right patients, the value for patients is high.
June 19, 2014 | Martin Zalesak, MD, PhD; Joyce S. Greenbaum, BA; Joshua T. Cohen, PhD; Fotios Kokkotos, PhD; Adam Lustig, MS; Peter J. Neumann, ScD; Daryl Pritchard, PhD; Jeffrey Stewart, BA; and Robert W. Dubois, MD, PhD
This study examines whether patients treated with specialty pharmaceuticals have improved outcomes compared with patients treated with conventional therapies, and evaluates costs associated with these treatments.
June 6, 2014 | Cate Douglass
With specialty pharmaceuticals carrying extremely high-and rising-costs, nonadherence and discontinuation of therapy is becoming even more commonplace. The value-based insurance design (V-BID) model, so termed by A. Mark Fendrick, MD, Dean Smith, PhD, and Michael Chernew, MD, promotes personalized patient care by easing access to specialty medications while reducing the number of prescribed treatments of lesser value as a replacement.
June 19, 2013 | Dea Belazi, PharmD, MPH
August 2, 2012 | William N. Kelly, PharmD, FISPE; Jeoffrey Stross, MD; James Jorgenson, MS, RPH, FASHP; and Douglas E. Miller, PharmD
Strategies for controlling use of specialty pharmaceuticals should focus on situations where these agents are used inappropriately and on improvement of the complex billing process.
January 11, 2011 | James A. Jorgenson, RPh, MS
Over the last 20 years, specialty pharmacy has grown and changed significantly to better manage high-cost drugs with challenging reimbursement issues.
April 26, 2010 | Jan E. Berger, MD, MJ
Can value-based benefit design be used in specialty pharmacy to address costs and align incentives between patients and payers?